27 published test results across 7 vendors · latest: 23 Apr 2026
| # | Vendor | Tests | Price/mg | Score |
|---|---|---|---|---|
| 1 | PPeptide-S Unverified | 4 | $3.30 | 61 |
| 2 | AAnlv Biotechnology Unverified | 3 | — | 59 |
| 3 | PPolaris Peptides | 6 | $12.75 | 52 |
| 4 | QQing Li Peptide Unverified | 3 | $3.00 | 48 |
| 5 | PParamount Peptides | 3 | $37.50 | 48 |
| 6 | UUther Unverified | 4 | — | 45 |
| 7 | SSkye Peptides | 4 | $16.01 | 40 |
Computed from publicly published third-party results. How scoring works · every listing is free and un-buyable. Vendors marked Unverified appear for their published results but are left out of the vendor rankings.
Survodutide is Boehringer Ingelheim’s GLP-1 and glucagon dual agonist, with phase 2 results in liver disease strong enough to earn FDA breakthrough designation for MASH in 2024, and phase 3 obesity data in April 2026 showing up to 16.6% mean weight loss at 76 weeks.
This is one of the thinnest markets we track as a full page: 27 published tests across 7 vendors. The spread is the warning sign. Published pricing runs $3.00 to $37.50 per milligram among scored sellers, a twelve-fold range on a board whose scores span just 47 to 64, and the freshest leader dates to January 2026 with others back in mid-2025. Thin, stale, and wildly repriced is the exact profile where buyers get hurt, because there is not enough current data for the market to police itself.
Date first: anything without a 2026 test is history. Per-mg math second, on tested content rather than the label, because at these spreads an underfill is expensive. Verification third, against the issuing lab’s own records. The calculator handles the arithmetic once a verified vial exists; nothing handles an unverified one.
No, anywhere. It is in phase 3 trials for obesity and MASH, with more data expected through 2026. Vials sold today are research chemicals.
A thin market with few sellers and little fresh testing gives pricing nothing to anchor to. On deep boards like tirzepatide’s, competition compresses the spread; here it never has.
Its glucagon component drives liver fat reduction, which produced strong phase 2 MASH results and a breakthrough designation. The obesity and liver programs both continue in phase 3.
Nothing on this page is medical advice; compounds shown are sold for research purposes only. Data is aggregated from publicly published third-party results and traces to its source.